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patient subgroups. For example, in oncology, markers such as KRAS, HER-2/neu and 
BRCA 1,2 are used for prognosis and to direct treatment. To reflect this evolution, 
comparative effectiveness research programme designs and analytical methods 
must be able to detect important treatment effects and outcomes for specific patient 
subgroups. The emergence of patient-centered care adds further complexity to HTA 
data requirements. The systematic collection of patient-reported outcomes (PROs) 
and their application to medicine is far from standard in clinical practice, although 
many clinical trial programmes now include the collection of PROs. For products 
in development, data generation plans must reflect ongoing changes and evolving 
complexities. We will review the growing range of methods employed in clinical 
effectiveness research, and show how personalised medicine and patient outcome 
programmes can strengthen HTA data packages.
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Objectives: Cost-effectiveness Analysis (CEA) and the calculation of the 
Incremental Cost-Effectiveness Ratio (ICER) together with its comparison with a 
threshold such as Gross Domestic Product (GDP)/capita, have long been used to 
assess the value for money of a new intervention compared with a comparator 
that this new intervention precisely seeks to displace. In this paper we show the 
paradoxical increase in cost-effective price using data from middle, low and very 
low income settings. MethOds: Using the introduction of rotavirus vaccination 
compared with no-vaccination as the example. We create a theoretical framework 
for calculating the ICER by gradually decreasing the investment for treatment of 
rotavirus related disease (the ‘no-vaccination comparator’) representing different 
countries with different GDP levels and decreasing levels of existing health care 
investment. We compare these results with an analysis of cost-effectiveness using 
real data from 9 countries representing a range of different GDP levels. Results: 
The theoretical framework works well in situations where the GDP/capita exceeds 
$10,000 – as expected the cost-effective price decreases with a decrease in the 
GDP/capita. Below this the scant investment in health care infrastructure, thereby 
reducing potential cost-offsets, coupled with the significant increase in the poten-
tial effect gain, results in a much wider margin between a cost-neutral and cost-
effective price that could effectively be set using this approach. cOnclusiOns: 
Although Cost-Effectiveness Analysis is widely used to assess the value for money 
of a new intervention for a particular price, we would argue that where investment 
in health care is low and disease burden is high, the use of CEA leads to paradoxes 
in price-setting.
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Objectives: Presents a reengineering process of the distribution of drugs into the 
hospital, analyzing all the options available in the market, and looking for alterna-
tive solutions that may be more cost-effective. MethOd: The processes and sub-
processes in the cycle from prescribing, distribution, and drug administration, are 
defined and discussed based on studies of medication errors (ME). The differential 
analysis is performed on the subprocesses. As technique for finding creative solu-
tions (new cost-effective alternatives) apply the Theory of Constraints (TOC), and the 
TRIZ methodology. Results: Since patient safety can distinguish four processes: 
prescription (about 40% of ME), transcription, distribution (about 10% each), and 
administration (about 40% of ME). In the administration, avoided ME before they 
reach the patient are minimal (only 2%). In the prescription/transcription there 
are 4 options: manual prescription, preprinted sheets, electronic prescription, 
and assisted prescription. In the distribution has 3 options: clasical SUD, filling 
carts using automated carousels, and automated dispensing systems (ADS). For 
administration there are other 3 options: manual record, electronic registration, and 
registration across the barcode. The most expensive option would be the introduc-
tion of ADS in all plants (1.4 million€ for a hospital of 280 beds). But these teams 
only reduces errors about 10% of all ME. Applying the TOC and TRIZ, investment in 
electronic prescribing, and administration with barcodes is the most cost-effective. 
Dose-day (sending medication for one day but not rated by patient) could be the 
most efficient system by simplifying processes. The error difference between Dose-
day, and SDU can be annulled by the advantages of the assisted prescription, and 
administration with barcode cOnclusiOns: It is surprising to invest large sums in 
improving distribution processes (ADS) - where the fewest mistakes occurs - instead 
of prescribing and administration. The dose-day with barcode administration would 
be the most cost-effective theoretical-model.
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Objectives: The R&D costs of a new drug approximate $1.3 billion and are increas-
ing due partly to regulatory hurdles and development costs. There is a need for 
smarter investments, which consider the requirements of regulatory bodies, 
increasing the chances of securing market access and high return on investment. We 
describe how health economic methods could support capital investment decisions 
in funding, valuing and bringing new pharmaceuticals to market. MethOds: A lit-
erature review was performed on health economic and capital investment methods. 
The different analyses were mapped to the commercial roadmap and R&D pipeline 
the near future, and similar levels of efficacy and acquisition cost as key compara-
tors In rare circumstances conducting an STA may not be cost-effective. It is possible 
that this can be predicted early in the STA process and we propose criteria to aid in 
this decision. When these criteria are met the possibility of “unreferring” the topic 
is likely to be the most cost-effective option.
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Objectives: To call attention to the problems resulting from the National Institute 
for Health and Care Excellence’s (NICE) recent revision to their methods guidance 
on discounting, which recommends applying a lower discount rate than the refer-
ence case rate in selected cases. MethOds: NICE’s reference case discount rate for 
costs and health effects is 3.5%. In 2011 NICE amended their economic appraisal 
guidelines recommending differential discounting of costs and health effects at 
3.5% and 1.5% respectively in selected cases. A recently published article in Value in 
Health criticised this amendment on a number of grounds, including ambiguity over 
what are the eligible selected cases; the lack of rationale for selective application 
of differential discounting; the apparent inconsistencies that unjustified selective 
application give rise to; and, the size of the differential between the two discount 
rates. In April 2013 NICE published a comprehensive revision of their methods guide-
lines, in which equal discounting of costs and effects at 1.5% in selected cases is 
now recommended. Results: While NICE’s new 2013 guidance no longer includes 
an unjustified differential between the discount rate on costs and health effects, 
it still recommends the application of lower discount rates in selected cases. The 
revised guidance still offers no rationale for such selective application of lower dis-
count rates. This means that many of problems described in the recently published 
critique of the 2011 amendment still apply to the new 2013 guidance, including a 
particularly worrying potential for age discrimination. cOnclusiOns: NICE’s selec-
tive application of lower discount rates in certain cases is not justified and leads to 
inconsistencies in the appraisal of different interventions. NICE is urged to again 
revise their discounting guidance, this time ensuring all interventions are treated 
equally and are subject to the same discount rates.
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Most cost-effectiveness models for evaluation of cancer care compare interventions 
within a single treatment line. However, to investigate the full impact of a new 
treatment, also downstream effects must be taken into account. Furthermore, most 
models are based on observed clinical states, whilst these observations depend on 
the timing of examinations and the choice of diagnostic test. To evaluate the poten-
tial of new treatments and diagnostics, the underlying disease process needs to be 
modeled including the interaction with diagnostics and treatment.Objectives: 
To build a flexible framework for a disease model, that simulates cancer progres-
sion to obtain clinical, patient and economic outcomes, while taking diagnostics 
treatment pathways and surveillance schedules into account . MethOds: The 
modeling framework discerns two levels to describe disease progression, the level 
of the patient and the tumor. At the patient level, an individual is characterized 
by clinical states; “primary tumor only”, “local recurrence”, “regional recurrence”, 
“distant metastasis, stable”, “distant metastasis, progressing” and “death”. The 
clinical state is derived from disease development at the tumor level. Seven tumor 
growth states are defined: “absent tumor”, “dormant tumor”, “micro tumor”, “small 
macro tumor”, “medium macro tumor”, “large macro tumor”, “symptomatic tumor”. 
Melanoma progression was used as a case study. The model simulates, in parallel, 
11 possible tumor sites, ranging from “local” to “regional” and “distant metastatic” 
locations. Sites were chosen because they are associated with different treatment 
and prognosis. The disease model is complemented with a treatment and surveil-
lance module. In this module, treatment choices in each of the clinical states are 
specified. Treatment choice may depend on patient and tumor features, and subse-
quently influences rate of transitioning between tumor growth states. For surveil-
lance, timing of surveillance visits, techniques used and their detection rate(s) are 
specified. cOnclusiOns: The proposed framework provides a flexible and widely 
applicable cancer modeling design.
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Defining value and generating innovation in health care relies increasingly on real 
world evidence. Consequently, there is an ongoing evolution in the data needs for 
health technology assessment (HTA). Three key elements of data generation are 
comparative effectiveness, personalised medicine and patient-centred outcomes. 
Integrating these three to support synthesis via systematic reviews, meta-analyses 
and modeling is necessary to maximise value and drive innovation. Effectiveness 
is not just about reduced morbidity and mortality. It now covers quality of life, 
patient satisfaction, intermediate endpoints, and screening/diagnosis/monitoring. 
Additionally, there is a shift away from effectiveness versus placebo to compara-
tive effectiveness versus other technologies or standards of care in the real world, 
focusing on the effect on health outcomes in defined patient populations based on 
ethnicity, comorbidities or age. Personalised medicine signals another shift of focus 
away from broad, homogenous patient populations to small, more-or-less defined 
